These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
62. Broadening Specificity and Enhancing Cytotoxicity of Adoptive T Cells for Nasopharyngeal Carcinoma Immunotherapy. Faè DA; Martorelli D; Mastorci K; Muraro E; Dal Col J; Franchin G; Barzan L; Comaro E; Vaccher E; Rosato A; Dolcetti R Cancer Immunol Res; 2016 May; 4(5):431-40. PubMed ID: 27009165 [TBL] [Abstract][Full Text] [Related]
63. Targeting the stroma by T cells to limit tumor growth. Zhang B Cancer Res; 2008 Dec; 68(23):9570-3. PubMed ID: 19047130 [TBL] [Abstract][Full Text] [Related]
64. [Molecular targets for development of cancer immunotherapy]. Kawakami Y Nihon Rinsho; 2012 Nov; 70 Suppl 8():144-8. PubMed ID: 23513828 [No Abstract] [Full Text] [Related]
66. Tumor immunotherapy: the tumor cell as an antigen-presenting cell. Ostrand-Rosenberg S Curr Opin Immunol; 1994 Oct; 6(5):722-7. PubMed ID: 7826527 [TBL] [Abstract][Full Text] [Related]
67. T Cell Receptors for Gene Transfer in Adoptive T Cell Therapy. Sharma P; Kranz DM Crit Rev Immunol; 2019; 39(2):105-122. PubMed ID: 31679251 [TBL] [Abstract][Full Text] [Related]
68. Efficient amplification of melanoma-specific CD8+ T cells using artificial antigen presenting complex. Chang J Exp Mol Med; 2006 Dec; 38(6):591-8. PubMed ID: 17202834 [TBL] [Abstract][Full Text] [Related]
69. Personalized Therapy: Tumor Antigen Discovery for Adoptive Cellular Therapy. Yee C; Lizee GA Cancer J; 2017; 23(2):144-148. PubMed ID: 28410303 [TBL] [Abstract][Full Text] [Related]
70. Killer artificial antigen-presenting cells deplete alloantigen-specific T cells in a murine model of alloskin transplantation. Shen C; He Y; Cheng K; Zhang D; Miao S; Zhang A; Meng F; Miao F; Zhang J Immunol Lett; 2011 Aug; 138(2):144-55. PubMed ID: 21513739 [TBL] [Abstract][Full Text] [Related]
71. T-cell adoptive immunotherapy using tumor-infiltrating T cells and genetically engineered TCR-T cells. Ikeda H Int Immunol; 2016 Jul; 28(7):349-53. PubMed ID: 27127191 [TBL] [Abstract][Full Text] [Related]
72. On immunotherapies and cancer vaccination protocols: a mathematical modelling approach. Joshi B; Wang X; Banerjee S; Tian H; Matzavinos A; Chaplain MA J Theor Biol; 2009 Aug; 259(4):820-7. PubMed ID: 19446568 [TBL] [Abstract][Full Text] [Related]
73. Dendritic cells in cancer immunotherapy. Gunzer M; Grabbe S Crit Rev Immunol; 2001; 21(1-3):133-45. PubMed ID: 11642600 [TBL] [Abstract][Full Text] [Related]
74. Soluble MHC class I complexes for targeted immunotherapy. Schappert A; Schneck JP; Suarez L; Oelke M; Schütz C Life Sci; 2018 Sep; 209():255-258. PubMed ID: 30102903 [TBL] [Abstract][Full Text] [Related]
75. To bead or not to bead. Dudley ME J Immunother; 2003; 26(3):187-9. PubMed ID: 12806272 [TBL] [Abstract][Full Text] [Related]
76. Cancer immunotherapy utilizing gene-modified T cells: From the bench to the clinic. Duong CP; Yong CS; Kershaw MH; Slaney CY; Darcy PK Mol Immunol; 2015 Oct; 67(2 Pt A):46-57. PubMed ID: 25595028 [TBL] [Abstract][Full Text] [Related]
77. Recent Advances in Polymeric Nanomedicines for Cancer Immunotherapy. Lee ES; Shin JM; Son S; Ko H; Um W; Song SH; Lee JA; Park JH Adv Healthc Mater; 2019 Feb; 8(4):e1801320. PubMed ID: 30666822 [TBL] [Abstract][Full Text] [Related]
78. In vivo administration of artificial antigen-presenting cells activates low-avidity T cells for treatment of cancer. Ugel S; Zoso A; De Santo C; Li Y; Marigo I; Zanovello P; Scarselli E; Cipriani B; Oelke M; Schneck JP; Bronte V Cancer Res; 2009 Dec; 69(24):9376-84. PubMed ID: 19934317 [TBL] [Abstract][Full Text] [Related]